{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:58:46Z","timestamp":1790539126316,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clcc.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:18:02Z","timestamp":1788362282000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1796-6918","authenticated-orcid":false,"given":"Simar","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi J.","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2026.08.006_bib0001","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.08.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100960","article-title":"Beyond EGFR inhibitors in advanced colorectal cancer: targeting BRAF and HER2","volume":"47","author":"Dao","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clcc.2026.08.006_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-021-00827-2","article-title":"Defining and targeting BRAF mutations in solid tumors","volume":"22","author":"Halle","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clcc.2026.08.006_bib0004","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s11033-013-2974-8","article-title":"Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies","volume":"41","author":"Cui","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.clcc.2026.08.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102996","article-title":"Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.clcc.2026.08.006_bib0006","article-title":"Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada","volume":"43","author":"Phillips","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.clcc.2026.08.006_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245748","article-title":"The impact of BRAF mutation status on survival outcomes and treatment patterns among metastatic colorectal cancer patients in Alberta, Canada","volume":"15","author":"Sutherland","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clcc.2026.08.006_bib0008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0b013e31824430d7","article-title":"BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features","volume":"36","author":"Pai","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clcc.2026.08.006_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.08.006_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.08.006_bib0011","unstructured":"Colon cancer (Version 1.2024). Available at: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/colon-patient.pdf. Accessed: March 26, 2025"},{"key":"10.1016\/j.clcc.2026.08.006_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2022.07.013","article-title":"Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) \u2013 a case series","volume":"174","author":"Rausch","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2026.08.006_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2026.08.006_bib0014","unstructured":"Canadian Agency for Drugs and Technologies. CADTH reimbursement review, provisional funding algorithm, indication: metastatic colorectal cancer. Canadian Agency for Drugs and Technologies. Available at: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/PH0062-mCRC_Rapid_Algorithm_Report.pdf. Accessed: March 26, 2025."},{"key":"10.1016\/j.clcc.2026.08.006_bib0015","unstructured":"Institut National D\u2019Exellence en Sant\u00e9 et en Services Sociaux. Braftovi, Cancer colorectal m\u00e9tastatique. Institut National D\u2019Exellence en Sant\u00e9 et en Services Sociaux. Available at: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Juin_2021\/Braftovi_2021_05.pdf. Accessed: March 26, 2025."},{"key":"10.1016\/j.clcc.2026.08.006_bib0016","unstructured":"Clinical practice guideline on metastatic colorectal cancer, version 13. Alberta Health Services. 2025. Available at: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-gi003-colorectal-metastatic.pdf. Accessed: August 01, 2025."},{"key":"10.1016\/j.clcc.2026.08.006_bib0017","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clcc.2026.08.006_bib0018","article-title":"Targeting BRAF V600E in metastatic colorectal cancer: where are we today?","volume":"16","author":"Guerrero","year":"2022","journal-title":"Ecancermedicalscience"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:48:40Z","timestamp":1790538520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"alternative-id":["S1533002826000678"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.006","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}